Home

Changing the Face of Allogeneic HCT With Novel Engineered Cellular Therapeutics

CME/CNE/CPE

Thursday, September 18, 2025 | 2:00 PM - 2:30 PM TZ

Supported by an independent educational grant from Gamida Cell.

overview

Immerse yourself for 30 minutes in a live educational event where you will hear Dr Gary Schiller review recent advancements in novel therapeutics used for graft engineering to advance clinical outcomes for patients receiving allogeneic hematopoietic cell transplantation (alloHCT). Dr Schiller will review the need for these therapies in adult patients who do not have a matched donor, emphasizing the rationale to have these novel therapeutics available as options for this patient population. Key data will be presented supporting the use of approved and emerging novel engineered cellular therapies with an emphasis on efficacy, safety, and the optimal integration of these agents into clinical practice. You will have the opportunity to hear Dr Schiller’s expert perspectives on this vital topic as well as engage with and ask him questions. Mark your calendar so you don’t miss this exciting, educational event!

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

faculty

Gary Schiller, MD

Professor

Division of Hematology/Oncology

Department of Medicine

Director, Hematological Malignancy/Stem Cell Transplantation

David Geffen School of Medicine at UCLA

Los Angeles, California

AGENDA

1:00 PM TZ

Welcome and Introduction

John Doe, MD

1:30 PM TZ

Introduction Medical Term

Lynn Doe, MD

2:00 PM TZ

Management of Acute Leukemia for the Community Healthcare Team

Jane Doe, MD

2:30 PM TZ

Panel Discussion

Kelly Doe, MD

5:00 PM TZ

Audience Q&A

Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.

*Video encouraged*

TARGET AUDIENCE

This educational activity is intended for an audience of hematologist/oncologists, including transplant specialists, nurse practitioners, nurses, pharmacists, and other members of the hematopoietic cell transplantation (HCT) care team in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to evaluate advancements in novel cellular therapies used for graft engineering to optimize clinical outcomes in allogeneic hematopoietic cell transplantation (alloHCT).

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Current options for alloHCT in patients who do not have a fully matched adult donor [item]Clinical trial data for novel engineered cellular therapies in alloHCT [/list] [para]Demonstrate greater confidence in their ability to[/para] [LIST] [ITEM]Assess the role of novel engineered cellular therapies in alloHCT[/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold][break] Medscape, LLC designates this live activity for a maximum of 0.50 [bold] [italic]AMA PRA Category 1 Credits™[/italic] [/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [break][break] [bold]For Nurses[/bold][break] Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs [break][break] [bold]For Pharmacists[/bold][break] Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-25-303-L01-P).